Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience

Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience

ABSTRACT Background Recently, a plethora of novel systemic agents have been incorporated into the therapeutic armamentarium of advanced urothelial carcinoma (aUC). The antibody–drug conjugate (ADC), enfortumab vedotin (EV), has demonstrated relevant clinical benefit in patients with aUC refractory t...

Full description

Saved in:
Bibliographic Details
Main Authors: Mimma Rizzo, Franco Morelli, Yüksel Ürün, Sebastiano Buti, Se Hoon Park, Maria T. Bourlon, Enrique Grande, Francesco Massari, Johannes Landmesser, Alexandr Poprach, Hideki Takeshita, Giandomenico Roviello, Zin W. Myint, Lazar Popovic, Andrey Soares, Halima Abahssain, Patrizia Giannatempo, Javier Molina‐Cerrillo, Lorena Incorvaia, Samer Salah, Annalisa Zeppellini, Fernando Sabino Marques Monteiro, Camillo Porta, Shilpa Gupta, Matteo Santoni
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:Cancer Medicine
Subjects:
ARON‐2 study
chemotherapy
enfortumab vedotin
NCT05290038
pembrolizumab
real‐world data
Online Access:https://doi.org/10.1002/cam4.70479
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70479

Similar Items